Description
This combination pairs CJC-1295 (a GHRH analog without DAC) with Ipamorelin (a selective ghrelin receptor agonist). It is studied for synergistic stimulation of growth hormone (GH) release and downstream IGF-1 activity, making it one of the most widely researched GH-axis peptide stacks.
Benefits
- Synergistic GH release — pairing GHRH and GHRP pathways for greater effect.
- Muscle recovery — studied for lean mass support and faster regeneration.
- Fat metabolism — linked to improved body composition in research models.
- Bone health — interest in supporting bone density and strength.
- Anti-aging research — explored for GH/IGF-1 signaling benefits.
What researchers look at
- CJC-1295 (no DAC): truncated GHRH analog designed for pulsatile GH release.
- Ipamorelin: selective ghrelin receptor agonist with minimal off-target effects.
- Synergy: combined activation of pituitary GH release pathways.
- Research in muscle recovery, fat metabolism, and aging-related GH decline.
Quick Specs
- Form: Lyophilized peptide blend
- Net per vial: 10 mg (5 mg CJC-1295 + 5 mg Ipamorelin)
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Components: CJC-1295 (no DAC), Ipamorelin
- Formula / M.W.: Peptide blend
- CAS: CJC-1295 (863288-34-0), Ipamorelin (170851-70-4)
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
JANOSHIK COA – THIRD-PARTY TESTING
https://janoshik.com/tests/93318-CJC1295Ipamorelin_5mg5mg_VPeptide_Canada_PIQC9HTSNN6P – December 11 2025
121732-CJCIPA_VPeptide_Canada_1UYTSEGTB142 – March 16 2026
